Skip to content

Marie Katrine Klose Nielsen

4 papers in the library · 23 citations · publishing 2024-2025

Papers

Sort Most recent Most cited

Molecular, haemodynamic and functional effects of LSD in the human brain

medRxiv June 18, 2025 Drummond E-Wen Mcculloch, Kristian Larsen, Annette Johansen et al. preprint

In this study, we provide the first study to integrate molecular and functional neuroimaging during psychedelic drug effects in humans. Using simultaneous PET-MRI technology, we describe multiple brain actions of lysergic acid diethylamide (LSD) in healthy volunteers. We quantify the occupancy of LSD at cerebral serotonin 2A receptors and show that LSD increases global cerebral blood flow and...

Stimulants for disorders of consciousness in the intensive care unit: a randomized, placebo-controlled trial.

Brain : a journal of neurology June 12, 2025 Marwan H Othman, Attila Géry Toury-Puel, Karen Irgens Tanderup Hansen et al. 7 citations

In the intensive care unit (ICU), management of unresponsive patients with brain injury focuses on preventing secondary brain damage. Therapeutic strategies that directly promote the recovery of consciousness are urgently needed. In an investigator-initiated, randomized, placebo-controlled, double-blind, cross-over trial, we studied the effects of apomorphine and methylphenidate in ICU patients...

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study

Journal of Psychopharmacology February 28, 2025 Dea Siggaard Stenbæk, Emil Deleuran Poulsen, Marie Katrine Klose Nielsen et al. 15 citations

Background: Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects of a single dose have not been investigated. Aims: To investigate the pharmacokinetics, feasibility, safety and efficacy of single-dose psilocybin therapy in AUD. Methods: This...

Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study

Research Square August 23, 2024 Mathias E. Jensen, Dea Siggaard Stenbæk, Catharina Messell et al. 1 citation

Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects a single dose have not been investigated. Aims To investigate the pharmacokinetics, feasibility, safety, and efficacy of single-dose psilocybin therapy in AUD. Methods This...